Primary indications of dynamic extension

The primary indications for dynamic extension with the SWiNGMED device are degenerative vertebral diseases, especially of the lumbar spine (low back pain).

In patients with degenerations of the spinal disc(s) (protrusion, prolapse) or pain caused by arthritic changes of the small vertebral joints, the therapy has shown successful results.

Further fields of application of SWiNGMED:

  • blockages of the small vertebral joints
  • facet joint syndrome
  • tensions of the back muscles
  • sciatica and radiculopathy
  • coxarthrosis

Further fields of application of SWiNGMED

The device is also perfectly suitable to treat patients presenting with:

  • blockages of the small vertebral joints
  • tensions of the back muscles
  • sciatica, sciatic neuralgia (pain that originates in the lumbar spine and descends down the leg)
  • (acute) lumbago
  • coxarthrosis
  • status post disc surgery (after healing)

Possible Contraindications

The following conditions must be considered possible contraindications for SwingMED treatments:

  • spinal fusion surgery and intervertebral disc prostheses
  • block vertebrae, depending on the severity of the fusion/hardening
  • tumours in the spinal area
  • spondylolisthesis and congenital deformations of the spine, cauda equina
  • bone fractures in the spinal area
  • Bekhterev syndrome, once the ossification stage has already been reached (in the early stage of the disease, therapy often helps ease the pain)
  • advanced osteoporosis
  • retinal detachment, glaucoma
  • vertigo, balance disturbances
  • epilepsy, neuroses, psychoses
  • clinically relevant diseases affecting the cardiovascular system (valvular heart diseases, cardiac dysrhythmia, angina pectoris, status post apoplexy, insufficiently controlled arterial hypertension, PAOD), of the lung (COPD, asthma), liver, kidney, intestines (hiatal hernia)
  • prostheses in the hip and knee (safe healing process? signs of loosening?)
  • serious ligament injuries of the lower extremity

In each case, the benefits and risks must be weighed. Mostly, the patient can undergo at least phases 1 and 2 of the therapy.